An autoantibody associated with IBM has also been recognized, which is detected in up to 70% of patients and is directed against cytosolic 5′-nucleotidase 1A (NT5c1A) (21–23), and has quickly gained status as a diagnostic biomarker (24). Here, NT5C1A is linked to inclusion body myositis.